A Phase II Clinical Study Evaluating the Safety, Tolerability,Pharmacokinetics, and Preliminary Efficacy of JS212 andJS213 as Monotherapy and in Combination in Patients Withadvanced Malignant Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Shanghai Junshi Bioscience Co., Ltd.
Sun Yat-sen University
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Sun Yat-sen University
Shanghai Chest Hospital
Sun Yat-sen University
West China Hospital
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Second Affiliated Hospital, School of Medicine, Zhejiang University
Jinling Hospital, China
Tianjin Medical University Cancer Institute and Hospital
Sun Yat-sen University
Icahn School of Medicine at Mount Sinai
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
University of Pittsburgh
Icahn School of Medicine at Mount Sinai
Stanford University
University of Chicago
First Affiliated Hospital of Zhejiang University
Tang-Du Hospital
Sun Yat-sen University
China Medical University, China
Sun Yat-sen University
Fudan University
Zhongnan Hospital
Tianjin Medical University Cancer Institute and Hospital
First Affiliated Hospital of Guangxi Medical University
First Affiliated Hospital of Zhejiang University
Shandong Cancer Hospital and Institute
China Medical University, China
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Fudan University